VistaGen Therapeutics (VTGN) to Release Earnings on Thursday

VistaGen Therapeutics (NASDAQ:VTGN) is expected to issue its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.3650) per share and revenue of $0.50 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 5:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Monday, June 15th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03). VistaGen Therapeutics had a negative return on equity of 133.02% and a negative net margin of 5,487.01%.The firm had revenue of $0.47 million for the quarter, compared to the consensus estimate of $0.40 million. During the same period last year, the firm earned ($1.67) EPS. On average, analysts expect VistaGen Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

VistaGen Therapeutics Trading Up 1.7%

VTGN opened at $0.24 on Tuesday. The stock has a market capitalization of $10.05 million, a P/E ratio of -0.13 and a beta of 0.41. The stock has a 50-day moving average price of $0.43 and a 200-day moving average price of $0.54. VistaGen Therapeutics has a 12-month low of $0.20 and a 12-month high of $5.14.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, VistaGen Therapeutics has an average rating of “Reduce” and an average target price of $0.95.

Institutional Trading of VistaGen Therapeutics

Several hedge funds have recently added to or reduced their stakes in VTGN. Virtu Financial LLC bought a new position in shares of VistaGen Therapeutics during the fourth quarter valued at about $25,000. Cubist Systematic Strategies LLC bought a new stake in shares of VistaGen Therapeutics in the 1st quarter valued at about $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in VistaGen Therapeutics during the 3rd quarter valued at about $39,000. Tudor Investment Corp ET AL purchased a new stake in VistaGen Therapeutics during the 4th quarter valued at about $50,000. Finally, Bank of America Corp DE grew its position in VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after acquiring an additional 19,331 shares during the last quarter. 78.39% of the stock is owned by institutional investors.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.